Your browser doesn't support javascript.
loading
Neutropenic Sepsis in the Intensive Care Unit: Differences in Clinical Profile and Outcomes According to the Cause of Neutropenia.
MacPhail, Aleece; Dendle, Claire; Slavin, Monica; Weinkove, Robert; Bailey, Michael; Pilcher, David; McQuilten, Zoe.
Affiliation
  • MacPhail A; School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
  • Dendle C; Department of Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
  • Slavin M; Department of Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
  • Weinkove R; School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
  • Bailey M; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Pilcher D; National Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • McQuilten Z; Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
Open Forum Infect Dis ; 11(6): ofae289, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38868301
ABSTRACT

Background:

Neutropenic sepsis frequently requires admission to an intensive care unit (ICU). Differences between subgroups of patients with neutropenic sepsis are not well characterized.

Aims:

To investigate clinical outcomes among patients with neutropenic sepsis and hematological malignancy, metastatic solid cancer, or no cancer diagnosis.

Methods:

Retrospective cohort study of all patients admitted to ICU in Australia or New Zealand between January 2000 and December 2022 with a primary admission diagnosis of sepsis and total white cell count <1.0 × 109 cells/L.

Results:

We identified 8617 ICU admissions with neutropenic sepsis (hematological malignancy n = 4660; metastatic solid cancer n = 1034; no cancer n = 2800). Patients with hematological malignancy were younger (median, 61.5 years) with low rates of chronic comorbidities (4.7%) and were usually admitted to ICU from the ward (67.4%). Mechanical ventilation rates were 20.2% and in-hospital mortality was 30.6%. Patients with metastatic solid cancers were older (median, 66.3 years), with higher rates of chronic comorbidities (9.9%), and were usually admitted to the ICU from the emergency department (50.8%). Mechanical ventilation rates were 16.9% and in-hospital mortality was 42.4%. Patients with no documented cancer had highest rates of mechanical ventilation (41.7%) and mortality (46.3%). Neutropenia was independently associated with mortality among patients with solid cancers or no cancer but did not confer increased risk among patients with hematological malignancy (odds ratio, 0.98; 95% confidence interval, .90-1.06; P = .60).

Conclusions:

Patients with neutropenic sepsis and hematological malignancy, metastatic solid cancer, or no cancer diagnosis constitute 3 distinct clinical groups. Management approaches should be tailored accordingly.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2024 Document type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2024 Document type: Article Affiliation country: Australia